{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:39:06Z","timestamp":1791275946077,"version":"4.1.0"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1136\/ard.2010.140582","type":"journal-article","created":{"date-parts":[[2011,2,21]],"date-time":"2011-02-21T09:33:24Z","timestamp":1298280804000},"page":"i77-i84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"special_numbering":"S1","title":["Psoriatic arthritis: update on pathophysiology, assessment and management"],"prefix":"10.1016","volume":"70","author":[{"given":"Philip J","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1136\/ard.2010.140582_bib1","first-page":"114","article-title":"Novel association of HCP5 gene in psoriatic arthritis [abstract]","volume":"69","author":"Boudreau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s11926-010-0107-0","article-title":"Update on biomarkers in psoriatic arthritis","volume":"12","author":"Chandran","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/ard.2010.140582_bib3","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/art.22024","article-title":"Distinct synovial immunopathologic characteristics of juvenile-onset spondylarthritis and other forms of juvenile idiopathic arthritis","volume":"54","author":"Kruithof","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib4","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/1529-0131(199907)42:7<1481::AID-ANR23>3.0.CO;2-E","article-title":"Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis","volume":"42","author":"Reece","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib5","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1136\/ard.2005.050963","article-title":"Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment","volume":"65","author":"van Kuijk","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib6","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1002\/art.20518","article-title":"Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate","volume":"50","author":"Kane","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/ard.2003.018085","article-title":"Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis","volume":"63","author":"Goedkoop","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib8","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1002\/art.21426","article-title":"Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies","volume":"52","author":"Kruithof","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib9","doi-asserted-by":"crossref","first-page":"R359","DOI":"10.1186\/ar1501","article-title":"Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy","volume":"7","author":"Baeten","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2010.140582_bib10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1136\/ard.2006.062042","article-title":"Ectopic lymphoid neogenesis in psoriatic arthritis","volume":"66","author":"Ca\u00f1ete","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib11","first-page":"96","article-title":"Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment","volume":"26","author":"Lories","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.24280","article-title":"Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis","volume":"61","author":"Fern\u00e1ndez-Sueiro","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib13","article-title":"Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program","author":"Gladman","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2010.140582_bib14","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11926-009-0045-x","article-title":"Clinical utility of ultrasonography in spondyloarthropathies","volume":"11","author":"Sturrock","year":"2009","journal-title":"Curr Rheumatol Rep"},{"issue":"23 Suppl 1","key":"10.1136\/ard.2010.140582_bib15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1468-3083.2009.03361.x","article-title":"Psoriasis and systemic inflammation: underdiagnosed enthesopathy","author":"Girolomoni","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1136\/ard.2010.140582_bib16","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1002\/art.22758","article-title":"The concept of a \u201csynovio-entheseal complex\u201d and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond","volume":"56","author":"McGonagle","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib17","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/art.22290","article-title":"Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders","volume":"56","author":"Benjamin","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/ar1934","article-title":"Magnetic resonance imaging in psoriatic arthritis: a review of the literature","volume":"8","author":"McQueen","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard.2010.140582_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11926-008-0049-y","article-title":"MRI in psoriatic arthritis: insights into pathogenesis and treatment response","volume":"10","author":"McQueen","year":"2008","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/ard.2010.140582_bib20","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1002\/art.21907","article-title":"Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow","volume":"54","author":"Appel","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib21","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1172\/JCI200316069","article-title":"Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis","volume":"111","author":"Ritchlin","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2010.140582_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/rheumatology\/keg475","article-title":"Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis","volume":"43","author":"Williamson","year":"2004","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard.2010.140582_bib23","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1172\/JCI23738","article-title":"Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis","volume":"115","author":"Lories","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1136\/ard.2010.140582_bib24","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib25","first-page":"1167","article-title":"Consensus on a core set of domains for psoriatic arthritis","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib26","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib27","first-page":"1417","article-title":"Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines","volume":"33","author":"Kavanaugh","year":"2006","journal-title":"J Rheumatol"},{"issue":"suppl 2","key":"10.1136\/ard.2010.140582_bib28","doi-asserted-by":"crossref","first-page":"ii49","DOI":"10.1136\/ard.2004.034165","article-title":"Psoriatic arthritis assessment tools in clinical trials","volume":"64","author":"Mease","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib29","first-page":"1426","article-title":"Assessment tools in psoriatic arthritis","volume":"35","author":"Mease","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib30","first-page":"1159","article-title":"Outcome measures in psoriatic arthritis","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"issue":"suppl 2","key":"10.1136\/ard.2010.140582_bib31","doi-asserted-by":"crossref","first-page":"ii65","DOI":"10.1136\/ard.2004.031237","article-title":"Psoriasis assessment tools in clinical trials","volume":"64","author":"Feldman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib32","first-page":"38","article-title":"Joint damage in psoriatic arthritis: How is it assessed and can it be prevented?","volume":"4","author":"Mease","year":"2006","journal-title":"Int J Adv Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib33","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jaad.2005.10.008","article-title":"Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective","volume":"54","author":"Mease","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2010.140582_bib34","first-page":"1733","article-title":"International spondyloarthritis interobserver reliability exercise\u2013the INSPIRE study: I. Assessment of spinal measures","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib35","first-page":"1740","article-title":"International spondyloarthritis interobserver reliability exercise\u2013the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis","volume":"34","author":"Gladman","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib36","first-page":"S789","article-title":"International multi-center psoriasis and psoriatic arthritis reliability trial (GRAPPA-IMPART): Assessment of skin, joints, nails, and dactylitis","volume":"56","author":"Chandran","year":"2007","journal-title":"Arthritis and Rheum"},{"key":"10.1136\/ard.2010.140582_bib37","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11926-006-0064-9","article-title":"Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology","volume":"8","author":"Mease","year":"2006","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/ard.2010.140582_bib38","first-page":"1423","article-title":"Psoriatic arthritis screening tools","volume":"35","author":"Qureshi","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib39","first-page":"1443","article-title":"Biological biomarkers in psoriatic disease. A review","volume":"35","author":"de Vlam","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib40","first-page":"1449","article-title":"Genetics of psoriasis and psoriatic arthritis: update and future direction","volume":"35","author":"Duffin","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib41","first-page":"1422","article-title":"Therapies for peripheral joint disease in psoriatic arthritis. A systematic review","volume":"33","author":"Soriano","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib42","first-page":"1431","article-title":"Therapies for axial disease in psoriatic arthritis. A systematic review","volume":"33","author":"Nash","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib43","first-page":"1435","article-title":"Therapies for psoriatic enthesopathy. A systematic review","volume":"33","author":"Ritchlin","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib44","first-page":"1439","article-title":"Therapies for dactylitis in psoriatic arthritis. A systematic review","volume":"33","author":"Helliwell","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib45","first-page":"1442","article-title":"Conventional systemic agents for psoriasis. A systematic review","volume":"33","author":"Strober","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib46","first-page":"1447","article-title":"Biologic therapies for psoriasis. A systematic review","volume":"33","author":"Boehncke","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib47","first-page":"1452","article-title":"Therapies for psoriatic nail disease. A systematic review","volume":"33","author":"Cassell","year":"2006","journal-title":"J Rheumatol"},{"issue":"suppl 3","key":"10.1136\/ard.2010.140582_bib48","doi-asserted-by":"crossref","first-page":"iii56","DOI":"10.1136\/ard.2007.078360","article-title":"Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility","volume":"66","author":"Bakker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib49","unstructured":"Mease PJ, Chernoff D,. Tighter control in RA: Exploring new paradigms. Clin Exp Rheumatol (In Press)."},{"key":"10.1136\/ard.2010.140582_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11926-008-0048-z","article-title":"Remission in psoriatic arthritis","volume":"10","author":"de Vlam","year":"2008","journal-title":"Curr Rheumatol Rep"},{"issue":"suppl 3","key":"10.1136\/ard.2010.140582_bib51","first-page":"115","article-title":"Development of a composite disease activity index in psoriatic arthritis [abstract]","volume":"69","author":"Mumtaz","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib52","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib54","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/acr.20162","article-title":"Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard.2010.140582_bib55","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"suppl 2","key":"10.1136\/ard.2010.140582_bib56","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib57","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3899\/jrheum.090346","article-title":"Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria","volume":"36","author":"Maksymowych","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib58","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3899\/jrheum090347","article-title":"Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design","volume":"36","author":"Maksymowych","year":"2009","journal-title":"J Rheumatol"},{"issue":"suppl 2","key":"10.1136\/ard.2010.140582_bib59","doi-asserted-by":"crossref","first-page":"ii74","DOI":"10.1136\/ard.2004.030783","article-title":"Psoriatic arthritis therapy:NSAIDs and traditional DMARDs","volume":"64","author":"Nash","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib60","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/BOR.0b013e32832c7832","article-title":"Psoriatic arthritis assessment and treatment update","volume":"21","author":"Mease","year":"2009","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib61","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib62","first-page":"241","article-title":"Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome","volume":"22","author":"Abu-Shakra","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib63","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/0002-9343(91)90667-M","article-title":"Methotrexate and histologic hepatic abnormalities: a meta-analysis","volume":"90","author":"Whiting-O'Keefe","year":"1991","journal-title":"Am J Med"},{"key":"10.1136\/ard.2010.140582_bib64","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jaad.2008.11.906","article-title":"Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference","volume":"60","author":"Kalb","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2010.140582_bib65","unstructured":"Raffayova H, Kungurov N, Baranauskaite A, et al. Infliximab plus methotrexate significantly improves rates of remission for methotrexate naive psoriatic arthritis (PsA) patients compared to methotrexate alone: The RESPOND trial [abstract].Arthritis and Rheum, 2009;60(suppl 10):S470\u20131."},{"key":"10.1136\/ard.2010.140582_bib66","first-page":"138","article-title":"Combination of adalimamab with cyclosporine-a against single therapy in refractory psoriatic arthritis: An interim analysis of an ongoing, 12-month open, three-arm, randomized trial","volume":"68","author":"Karanikolas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib67","first-page":"216","article-title":"Efficacy of anakinra (Kineret) in psoriatic arthritis, a clinical and immunohistological study","volume":"65","author":"Gibbs","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib68","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ"},{"key":"10.1136\/ard.2010.140582_bib69","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba","year":"2007","journal-title":"J Exp Med"},{"key":"10.1136\/ard.2010.140582_bib70","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib71","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib72","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib73","first-page":"136","article-title":"Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week effiacay and safety results of the randomized, placebo-controlled GO-REVEAL study","volume":"68","author":"Kavanaugh","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"suppl 3","key":"10.1136\/ard.2010.140582_bib74","first-page":"116","article-title":"Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results from the GO-REVEAL study [abstract]","volume":"69","author":"Kavanaugh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib75","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/ard.2009.111856","article-title":"Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions","volume":"69","author":"Van den Bosch","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib76","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.2005.041129","article-title":"Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis","volume":"65","author":"Zochling","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib77","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.21870","article-title":"Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study","volume":"54","author":"Mease","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib78","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jaad.2008.09.050","article-title":"Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study","volume":"60","author":"Mease","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2010.140582_bib79","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","article-title":"CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris","volume":"103","author":"Abrams","year":"1999","journal-title":"J Clin Invest"},{"issue":"suppl 10","key":"10.1136\/ard.2010.140582_bib80","first-page":"S472","article-title":"Abatacept in psoriatic arthritis: Results of a phase II study session [abstract]","volume":"60","author":"Mease","year":"2009","journal-title":"Arthritis and Rheum"},{"key":"10.1136\/ard.2010.140582_bib81","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1136\/ard.2010.140582_bib82","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/ard.2010.140582_bib83","unstructured":"Kimball AB, Gordon KB, Valdes JM, et al. Retreatment efficacy and long-term safety of the fully human, interleukin-12\/23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial. 17th Congress on the European Academy of Dermatology and Venereology, September, 2008, Paris, France."},{"key":"10.1136\/ard.2010.140582_bib84","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.coph.2004.04.003","article-title":"Interleukin-15: a new cytokine target for the treatment of inflammatory diseases","volume":"4","author":"McInnes","year":"2004","journal-title":"Curr Opin Pharmacol"},{"issue":"suppl 3","key":"10.1136\/ard.2010.140582_bib85","first-page":"116","article-title":"Rituximab in psoriatic arthritis: Results of an open label study [abstract]","volume":"69","author":"Mease","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard.2010.140582_bib86","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib87","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1136\/ard.2010.140582_bib88","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/art.1780401021","article-title":"Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death","volume":"40","author":"Wong","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib89","first-page":"2167","article-title":"Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis","volume":"33","author":"Han","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.2010.140582_bib90","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.semarthrit.2006.09.001","article-title":"Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis","volume":"36","author":"Kimhi","year":"2007","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.2010.140582_bib91","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1253\/circj.CJ-09-0274","article-title":"Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis","volume":"73","author":"Ku","year":"2009","journal-title":"Circ J"},{"key":"10.1136\/ard.2010.140582_bib92","first-page":"659","article-title":"TNF-alpha blcokade is associated with reduction of carotid intima-media thickness for patients with active psoriatic arthritis-A pilot study","volume":"68","author":"Tam","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1136\/ard.2010.140582_bib93","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724497446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724497446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.2010.140582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T06:14:49Z","timestamp":1737267289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724497446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":93,"alternative-id":["S0003496724497446"],"URL":"https:\/\/doi.org\/10.1136\/ard.2010.140582","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psoriatic arthritis: update on pathophysiology, assessment and management","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.2010.140582","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}